It is marketed by Pernix Therapeutics under the trade name Cedax.

Ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

It is also indicated for pneumonia, infections of the urinary tract, enteritis, and gastroenteritis.

[citation needed] Ceftibuten is active against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Proteus vulgaris, P. mirabilis, P. providence, Salmonella sp., Shigella sp., Enterobacter sp., and Streptococcus sp.

[citation needed] The following represents minimum inhibitory concentration (MIC) susceptibility data for a few clinically significant microorganisms: